BCEL
- Atreca, Inc.
()
Overview
Company Summary
Atreca, Inc., ticker symbol BCEL, is a biotechnology company that specializes in the field of immunotherapy. The company is focused on developing novel therapeutics for the treatment of a wide range of diseases, including cancer and autoimmune disorders.
Atreca takes a unique approach to drug discovery by leveraging its proprietary discovery platform called Immune Repertoire Capture (IRC). This technology allows the company to study the immune system at an individual patient level and identify clinically relevant antibodies that can be used to develop personalized therapeutics.
The IRC platform enables Atreca to analyze and decode the immune repertoire of patients, which refers to the collection of immune cells and antibodies in their bodies. This in-depth understanding of the patient's immune system helps Atreca identify and isolate highly specific antibodies with therapeutic potential.
Atreca's goal is to create a pipeline of therapeutic candidates based on these antibodies. The company's team of scientists and researchers work to develop these candidates into drugs that can be used to modulate the immune system and target specific disease indications.
By leveraging its unique technology, Atreca aims to discover and develop innovative immunotherapies that have the potential to significantly improve patient outcomes across various diseases. The company collaborates with partners and collaborators in academia, industry, and the medical community to advance its research and development efforts.
In summary, Atreca, Inc. is a biotechnology company that uses its proprietary technology to study the immune system at an individual level, identify disease-specific antibodies, and develop novel immunotherapies for the treatment of cancers and autoimmune disorders.